Trials / Conditions / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

8 registered clinical trials studyying B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plu NCT06738368	University of Washington	Phase 2
Recruiting	Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed NCT06918431	City of Hope Medical Center	Phase 2
Recruiting	Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelph NCT05453500	University of Washington	Phase 2
Recruiting	Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Re NCT03739814	National Cancer Institute (NCI)	Phase 2
Terminated	Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia NCT03488225	M.D. Anderson Cancer Center	Phase 2
Completed	Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia NCT02484430	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negati NCT02003222	National Cancer Institute (NCI)	Phase 3
Recruiting	Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia NCT01371630	M.D. Anderson Cancer Center	Phase 1 / Phase 2